AbbVie Inc (ABBV) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that develops, manufactures and commercializes advanced therapies for treating complex and serious diseases. It provides pharmaceutical drugs to treat conditions in rheumatology, gastroenterology, dermatology, oncology, virology and metabolic therapy areas. The company also offers medicines for neurological disorders and other serious health conditions. AbbVie discovers and develops novel medicines based on protein-based and targeted drug delivery technologies. The company its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses across the world. AbbVie is headquartered in North Chicago, Illinois, the US.

AbbVie Inc (ABBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 8
List of Figures 10
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 16
AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
AbbVie Inc, Pharmaceuticals & Healthcare, Deal Details 26
Asset Purchase 26
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 26
AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 27
AbbVie Acquires Rights to Ribasphere from Kadmon 28
Venture Financing 29
ApoGen Biotech Raises Additional USD4 Million in Series A Financing 29
Quentis Therapeutics Raises USD48 Million in Series A Financing 31
Jnana Therapeutics Raises USD50 Million in Series A Financing 32
Palleon Pharma Raises USD47.6 Million in Series A Financing 33
Disarm Therapeutics Raises USD30 Million in Series A Financing 34
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 35
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 37
CARMA Therapeutics Raises Fund through Venture Financing 39
ApoGen Biotech Raises USD7 Million in Series A Financing 40
Artios Pharma Raises USD33.2 Million in Series A Financing 41
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 43
Lodo Therapeutics Raises USD17 Million in Series A Financing 44
Alector Raises USD29.5 Million in Series D Financing 46
Petra Pharma Raises USD48 Million in Series A Financing 48
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 50
Stemcentrx Raises USD500 Million in Financing Round 52
Stemcentrx Raises USD250 Million in Financing Round 53
Stem CentRx Raises more than USD100 Million in Financing Round 54
AM-Pharma Raised USD15.8 Million in Series E Venture Financing 55
Virobay Raises USD8 Million in Extended Series B Financing 57
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 59
AuraSense Therapeutics Raises Funds Through Extended Series B Financing 61
Avaxia Biologics Raises US$11.4 Million In Series B Financing 62
Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 64
Partnerships 65
Tolero Pharma Enters into Research Agreement with AbbVie 65
IRICoR, University of Montreal Enter into Research Agreement with AbbVie 66
Oncternal Therapeutics Enters into Agreement with Pharmacyclics 68
Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 69
AbbVie Enters into Agreement with Alector 71
AbbVie and Harpoon Therapeutics Enter into Research Partnership 72
AbbVie and Turnstone Biologics Enter into Research Agreement 73
AbbVie and Bristol-Myers Squibb Enter into Agreement 74
AbbVie and Principia Biopharma Enter into Agreement 75
Argen-X Enters Into Agreement with AbbVie 76
Zebra Biologics Enters into Agreement with AbbVie 77
AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 78
AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 79
AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 80
AbbVie Enters into Agreement with BioArctic 81
X-Chem Enters into Co-Development Agreement with AbbVie 82
AbbVie and Bristol-Myers Squibb Enter into Agreement 83
AbbVie Enters into Research Agreement with University of Chicago 84
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 85
Philogen Enters into R&D Agreement with AbbVie 86
Synlogic Enters into R&D Agreement with AbbVie 87
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 88
AbbVie Deutschland Enters into Partnership Agreement with Eisai 89
Enterome Enters into Co-Development Agreement with AbbVie 90
Calico Expands Co-Development Agreement with AbbVie 91
Seattle Genetics Expands Co-Development Agreement With AbbVie 92
Myriad Genetics Expands Research Agreement with AbbVie 93
AbbVie Expands its Agreement with Galapagos 94
AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 96
Inventiva Extends Agreement with AbbVie 97
Licensing Agreements 98
AbbVie Exercises Option for Licensing Agreement with Argenx 98
Mylan Enters into Licensing Agreement with AbbVie 99
AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 100
E-Scape Enters into Licensing Agreement with AbbVie 101
Samsung Bioepis Enters into Licensing Agreement with AbbVie 102
AbbVie Exercises Option for Licensing Agreement with X-Chem 103
AbbVie Exercises Option for Licensing Agreement with Philogen 104
AbbVie Enters into Licensing Agreement with Pure MHC 105
AbbVie Enters into Licensing Agreement with Dong-A ST 106
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 107
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 109
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 111
AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimers Disease Therapy 112
AbbVie Enters into Licensing Agreement with Apogenix 113
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 114
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 115
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 116
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 117
F-star Bio Enters into Licensing agreement with AbbVie 118
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 119
Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 120
Equity Offering 121
Exicure Raises USD20 Million in Private Placement 121
Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 122
Pharmacyclics Completes Public Offering Of Shares For US$207 Million 123
AbbVie Spin Out from Abbott Laboratories 124
AbbVie Completes IPO 125
Debt Offering 126
AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 126
AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 127
AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 128
AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 129
AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 131
AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 133
AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 135
AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 137
AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 139
AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 141
AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 143
AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 145
AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 147
AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 149
AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 151
AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 152
AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 153
AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 154
Acquisition 155
AbbVie Acquires Stemcentrx 155
AbbVie Acquires Pharmacyclics 156
AbbVie Acquires ImmuVen from Serra Ventures 158
AbbVie Inc - Key Competitors 159
AbbVie Inc - Key Employees 160
AbbVie Inc - Locations And Subsidiaries 161
Head Office 161
Other Locations & Subsidiaries 161
Recent Developments 170
Strategy And Business Planning 170
Jan 16, 2018: AbbVie Expands Oncology Capability at the Companys Site in Ballytivnan, Sligo 170
Financial Announcements 171
Jul 27, 2018: AbbVie Reports Second-Quarter 2018 Financial Results 171
Apr 26, 2018: AbbVie Reports First-Quarter 2018 Financial Results 174
Jan 26, 2018: AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results 176
Oct 27, 2017: AbbVie Reports Third-Quarter 2017 Financial Results 178
Jul 28, 2017: AbbVie Reports Second-Quarter 2017 Financial Results 180
Apr 27, 2017: AbbVie Reports First-Quarter 2017 Financial Results 182
Jan 27, 2017: AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results 184
Corporate Communications 186
Aug 20, 2018: AbbVie announces 100 million donation to Ronald McDonald House Charities to support hospitalized children and their families 186
May 22, 2018: AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico 187
Jul 31, 2017: AbbVie Announces Delisting from Euronext Paris 189
Legal and Regulatory 190
Mar 28, 2018: AbbVie pays $5m to man who claims testosterone drug caused heart attack 190
Government and Public Interest 191
Dec 05, 2017: Bioethics International Releases the "Good Pharma Scorecard" in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 191
Mar 28, 2017: AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program 192
Product News 193
12/14/2017: LSTMs AWOL Consortium Celebrates 10-year Milestone 193
11/21/2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition 194
10/30/2017: Janssen Announces IMBRUVICA (ibrutinib) as the First Approved Treatment for Chronic Graft-Versus-Host Disease (cGVHD) Granted by Health Canada Priority Review 195
10/25/2017: Nail psoriasis data now part of HUMIRA label 197
10/24/2017: AbbVie to Present New Data on HUMIRA at the 2017 ACR/ARHP Annual Meeting 198
08/30/2017: China Food and Drug Administration approves IMBRUVICA (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs 200
08/29/2017: More Canadians have access to HUMIRA (adalimumab) for the treatment of Ulcerative Colitis 201
08/02/2017: U.S. FDA Approves IMBRUVICA (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) - A Serious, Potentially Life-Threatening Condition - After Failure of One or More Lines of Systemic Therapy 202
07/21/2017: AbbVie Receives CHMP Positive Opinion for HUMIRA (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis 204
06/28/2018: argenx receives second preclinical milestone payment under its development agreement with AbbVie 206
06/21/2018: AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, A New Pediatric Formulation of HUMIRA 207
06/13/2017: AbbVie Presents Real-World Data Evaluating the Relationship between Participation in a Patient Support Program and Outcomes in Patients with Moderate to Severe Rheumatoid Arthritis 208
06/11/2018: AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA 210
06/05/2017: New Data Presented at ASCO 2017 Finds IMBRUVICA (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia Treatment than Chemotherapy Agent Chlorambucil in Treatment-Nave Patients 211
05/22/2017: New cancer drug can prevent reactions to common airborne allergens 213
04/13/2017: argenx receives first preclinical milestone payment in AbbVie collaboration 214
04/11/2017: Scottish Medicines Consortium recommends Imbruvica (ibrutinib) for restricted use in patients with Chronic Lymphocytic Leukaemia in Scotland 215
03/30/2017: U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVies HUMIRA (adalimumab) Prescribing Information 216
03/23/2018: AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-a Monoclonal Antibody HUMIRA in the Treatment of Patients who have had an Inadequate Response to Conventional Therapy for Pustular Psoriasis 217
02/21/2018: Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA (Adalimumab) to manage their disease 218
01/26/2017: National Institute for Health and Care Excellence (NICE) approves Imbruvica (ibrutinib) for routine NHS use in patients with chronic lymphocytic leukaemia 219
01/19/2017: U.S. FDA Approves IMBRUVICA (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkins Lymphoma 220
Product Approvals 222
Jan 15, 2018: AbbVies Humira Rejects For Use Within NHS Scotland 222
Nov 13, 2017: Janssen-Cilags Imbruvica Rejects For Use Within NHS Scotland 223
Sep 28, 2017: NICE U-turn on Imbruvica(ibrutinib) means patients with Waldenstroms macroglobulinaemia can now access the only licensed novel agent available for this rare blood cancer 224
Jun 12, 2017: AbbVies Humira accepted for use in NHS Scotland 225
Jun 12, 2017: Janssen-Cilags Imbruvica Rejects For Use Within NHS Scotland 226
Apr 25, 2017: AbbVie Files Application for Humira in Japan for Additional Indication of Pustular Psoriasis 227
Apr 04, 2017: U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy 228
Jan 10, 2017: Australian Approval For Drug That Melts Leukaemia 229
Clinical Trials 230
Feb 12, 2018: AbbVie to Present Data on HUMIRA at 2018 American Academy of Dermatology Annual Meeting 230
Nov 21, 2017: AbbVie to Present Data on Ibrutinib at the 2017 American Society of Hematology Annual Meeting & Exposition 231
Nov 01, 2017: Janssen to Present Abstracts on IMBRUVICA (ibrutinib) at ASH 2017 233
Jun 24, 2017: European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids 235
Jun 19, 2017: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit with Single Agent Imbruvica (ibrutinib) vs Temsirolimus at First Relapse in Mantle Cell Lymphoma 236
Jun 05, 2017: Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukaemia Patients Treated with Imbruvica (ibrutinib), Including Those with High-Risk Disease, with Up to Four Years of Follow-Up 238
Jun 05, 2017: Long-Term IMBRUVICA (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease 240
May 17, 2017: Janssen to Present Data on Ibrutinib at the American Society of Clinical Oncology 242
May 14, 2017: IMBRUVICA (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 243
Apr 19, 2017: AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer 245
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie 246
Feb 24, 2017: Evaluating A Novel Chemo-free Combination Therapy for Lymphocytic Leukemia 247
Appendix 248
Methodology 248
About GlobalData 248
Contact Us 248
Disclaimer 248

List Of Tables


AbbVie Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
AbbVie Inc, Deals By Therapy Area, 2012 to YTD 2018 14
AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 16
AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 26
AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 27
AbbVie Acquires Rights to Ribasphere from Kadmon 28
ApoGen Biotech Raises Additional USD4 Million in Series A Financing 29
Quentis Therapeutics Raises USD48 Million in Series A Financing 31
Jnana Therapeutics Raises USD50 Million in Series A Financing 32
Palleon Pharma Raises USD47.6 Million in Series A Financing 33
Disarm Therapeutics Raises USD30 Million in Series A Financing 34
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 35
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 37
CARMA Therapeutics Raises Fund through Venture Financing 39
ApoGen Biotech Raises USD7 Million in Series A Financing 40
Artios Pharma Raises USD33.2 Million in Series A Financing 41
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 43
Lodo Therapeutics Raises USD17 Million in Series A Financing 44
Alector Raises USD29.5 Million in Series D Financing 46
Petra Pharma Raises USD48 Million in Series A Financing 48
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 50
Stemcentrx Raises USD500 Million in Financing Round 52
Stemcentrx Raises USD250 Million in Financing Round 53
Stem CentRx Raises more than USD100 Million in Financing Round 54
AM-Pharma Raised USD15.8 Million in Series E Venture Financing 55
Virobay Raises USD8 Million in Extended Series B Financing 57
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 59
AuraSense Therapeutics Raises Funds Through Extended Series B Financing 61
Avaxia Biologics Raises US$11.4 Million In Series B Financing 62
Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 64
Tolero Pharma Enters into Research Agreement with AbbVie 65
IRICoR, University of Montreal Enter into Research Agreement with AbbVie 66
Oncternal Therapeutics Enters into Agreement with Pharmacyclics 68
Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 69
AbbVie Enters into Agreement with Alector 71
AbbVie and Harpoon Therapeutics Enter into Research Partnership 72
AbbVie and Turnstone Biologics Enter into Research Agreement 73
AbbVie and Bristol-Myers Squibb Enter into Agreement 74
AbbVie and Principia Biopharma Enter into Agreement 75
Argen-X Enters Into Agreement with AbbVie 76
Zebra Biologics Enters into Agreement with AbbVie 77
AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 78
AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 79
AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 80
AbbVie Enters into Agreement with BioArctic 81
X-Chem Enters into Co-Development Agreement with AbbVie 82
AbbVie and Bristol-Myers Squibb Enter into Agreement 83
AbbVie Enters into Research Agreement with University of Chicago 84
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 85
Philogen Enters into R&D Agreement with AbbVie 86
Synlogic Enters into R&D Agreement with AbbVie 87
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 88
AbbVie Deutschland Enters into Partnership Agreement with Eisai 89
Enterome Enters into Co-Development Agreement with AbbVie 90
Calico Expands Co-Development Agreement with AbbVie 91
Seattle Genetics Expands Co-Development Agreement With AbbVie 92
Myriad Genetics Expands Research Agreement with AbbVie 93
AbbVie Expands its Agreement with Galapagos 94
AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 96
Inventiva Extends Agreement with AbbVie 97
AbbVie Exercises Option for Licensing Agreement with Argenx 98
Mylan Enters into Licensing Agreement with AbbVie 99
AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 100
E-Scape Enters into Licensing Agreement with AbbVie 101
Samsung Bioepis Enters into Licensing Agreement with AbbVie 102
AbbVie Exercises Option for Licensing Agreement with X-Chem 103
AbbVie Exercises Option for Licensing Agreement with Philogen 104
AbbVie Enters into Licensing Agreement with Pure MHC 105
AbbVie Enters into Licensing Agreement with Dong-A ST 106
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 107
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 109
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 111
AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimers Disease Therapy 112
AbbVie Enters into Licensing Agreement with Apogenix 113
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 114
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 115
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 116
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 117
F-star Bio Enters into Licensing agreement with AbbVie 118
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 119
Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 120
Exicure Raises USD20 Million in Private Placement 121
Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 122
Pharmacyclics Completes Public Offering Of Shares For US$207 Million 123
AbbVie Spin Out from Abbott Laboratories 124
AbbVie Completes IPO 125
AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 126
AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 127
AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 128
AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 129
AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 131
AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 133
AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 135
AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 137
AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 139
AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 141
AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 143
AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 145
AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 147
AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 149
AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 151
AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 152
AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 153
AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 154
AbbVie Acquires Stemcentrx 155
AbbVie Acquires Pharmacyclics 156
AbbVie Acquires ImmuVen from Serra Ventures 158
AbbVie Inc, Key Competitors 159
AbbVie Inc, Key Employees 160
AbbVie Inc, Subsidiaries 161

List Of Figures


AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 16

AbbVie Inc (ABBV) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that develops, manufactures and commercializes advanced therapies for treating complex and serious diseases. It provides pharmaceutical drugs to treat conditions in rheumatology,

USD 250 View Report

AbbVie Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

AbbVie Inc Company Profile is a detailed strategic and analytical report on AbbVie Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available